de Verneuil Vanina has sold 1,343 shares of Vir Biotechnology, Inc. as part of a restricted stock vesting. This transaction is significant as it reflects ongoing compensation practices within the biotechnology sector.

The sale was executed to cover tax obligations related to the equity award. The aggregate market value of the shares sold was approximately $15,221.96, indicating a structured approach to managing compensation that is common in the industry.

Background

de Verneuil Vanina is an officer at Vir Biotechnology, Inc., a company that operates in the biological products sector. The company is listed under the Central Index Key (CIK) 0001706431 and is traded on the NASDAQ. Recent filings show that Vanina has been active in trading shares, with multiple transactions reported throughout the year.

What the Filing Says

“Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.”

Impact

This sale may affect executive compensation strategies within the biotechnology sector, as it highlights the necessity for executives to manage their equity awards effectively. Other executives and stakeholders may take note of this transaction as they plan their own compensation strategies.

What's Next

The filing does not say what happens next.